• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3276 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: integrating innovations into social and health services systems]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: reducing the carbon footprint of anesthetic agents inhaled in the operating room during general anesthesia - strategies and challenges to consider]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to the management of people with cholangiocarcinoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of thrombectomy for the treatment of ischemic stroke in Québec – Portrait from 2017-2018 to 2019-2020]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: KIT D816V mutation detection by NAAT]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast cancer screening with breast tomosynthesis]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: linezolid plasma dosing]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of polypharmacy and use of potentially inappropriate medications among people aged 65 and over in Quebec]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: genomic medicine in healthcare systems - challenges and opportunities]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: judicious use of medical biology tests in the diagnosis and treatment of Helicobacter pylori infection]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Renal denervation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: delirium in elderly persons in emergency departments - prevention, assessment and management]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: equivalence of the positivity threshold of immunochemical fecal occult blood tests for colorectal cancer screening]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: non-physician prescribers' scope of practice]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Measles: diagnosis and detection]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketorolac for renal colic
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with substance use disorders
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: a 2023 update
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: a brief overview of indicators for care and service transitions of community-dwelling seniors with major neurocognitive disorder (MNCD) in Quebec]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: an overview of emergency department visits and hospitalizations among young people aged 6 to 25 for mental health and psychosocial issues in 2022–2023, compared to the pre-pandemic (2016–2020) and pandemic periods (2020–2022) of COVID-19]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: plasma sC5b-9 assay]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding newborn screening for congenital adrenal hyperplasia to the Quebec newborn blood screening program]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: healthcare systems in the future: what priorities guide innovation?]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dosing of a new generation anti-seizure panel by LC-MS/MS]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of chronic obstructive pulmonary disease in Quebec from 2016 to 2022 - healthcare Indicator results]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection: a health technology assessment
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors: a health technology assessment
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain: a health technology assessment
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment
2024     Ontario Health Sucrose octosulfate (SOS)-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders: a health technology assessment
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Ontario Health Minimally invasive bleb surgery for glaucoma: a health technology assessment
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2023     WorkSafeBC Cryoneurolysis for shoulder pain
2023     Ontario Health Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023     Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023     Ontario Health Robotic-assisted partial nephrectomy for kidney cancer
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023     WorkSafeBC Creatine supplementation for treating concussions
2023     WorkSafeBC Glutamine for treating concussions
2023     WorkSafeBC Koebner phenomenon in connective tissue
2023     WorkSafeBC The effect of pepper spray on human health
2023     WorkSafeBC Myalgic encephalomyelitis/chronic fatigue syndrome associated with mRNA COVID-19 vaccination
2023     WorkSafeBC Platelet rich plasma as treatment for medial epicondylitis
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of Intercept and Mirasol - pathogen reduction technologies for the treatment of labile blood products in Quebec]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: principles and criteria guiding the use of parent-child trio genomewide sequencing in constitutional genetics - a report to support the work of the RQDM]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2023     WorkSafeBC Low intensity pulsed ultrasound (LIPUS) for preventing fractures
2023     WorkSafeBC Efficacy of eye movement desensitization and reprocessing (EMDR) as treatment for major depression
2023     WorkSafeBC Firefighting and polycythemia vera
2023     WorkSafeBC HEPA filters and nanomaterials
2023     WorkSafeBC Hemorrhoids and heavy lifting
2023     WorkSafeBC Association between wearing orthosis and developing metatarsal stress fractures
2023     WorkSafeBC Causal association between firefighting and hypersensitivity pneumonitis
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Routine dental polishing for oral health
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Intraocular lenses for cataract surgery
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Refractive laser surgery for vision conditions
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine naloxone film versus tablets for opioid use disorder
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Case carts in surgical settings
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Anti–vascular endothelial growth factor drugs for age-related macular degeneration
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care ultrasound for guided central venous catheter insertion
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) IV acetaminophen for acute pain in emergency departments
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Semaglutide 2 mg for type 2 diabetes
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Midline and extended dwell catheters for IV antibiotics
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Radiofrequency ablation for chronic knee, hip, and shoulder pain
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Direct-acting antivirals for pediatric chronic hepatitis C virus infection